Cancer pain

Northwest Pain Care Selects eClinicalWorks Cloud EHR to Enable Faster Data-Driven Decisions at the Point of Care

Retrieved on: 
Tuesday, June 20, 2023

eClinicalWorks® , the largest ambulatory cloud EHR, today announced that Northwest Pain Care recently selected eClinicalWorks to help the practice provide comprehensive care, improve efficiency, and lower patient wait times with the industry’s first health information search tool, PRISMA .

Key Points: 
  • eClinicalWorks® , the largest ambulatory cloud EHR, today announced that Northwest Pain Care recently selected eClinicalWorks to help the practice provide comprehensive care, improve efficiency, and lower patient wait times with the industry’s first health information search tool, PRISMA .
  • The one patient, one record approach collates medical information from specialties, urgent care facilities, hospitals, and primary care providers to enable faster and more accurate decision-making.
  • View the full release here: https://www.businesswire.com/news/home/20230620201137/en/
    PRISMA will aid Northwest Pain Care in its mission to provide exceptional and effective management of acute, chronic, and cancer pain.
  • “With PRISMA, we can now access patient data at the point of care,” said Hilary Severn, practice manager of Northwest Pain Care.

Fentanyl False Claims Act Qui Tam Case Leads to $9M Settlement

Retrieved on: 
Thursday, June 1, 2023

PHILADELPHIA, June 1, 2023 /PRNewswire/ -- Kang Haggerty LLC announced today that they obtained a $9 Million settlement in a non-intervened fentanyl false claims act qui tam case against private equity firm Belhealth Investment Partners, its principals, Harold Blue, Inder Tallur, and Dennis Drislane, and its pharmacy portfolio companies, Linden Care and Quick Care.

Key Points: 
  • PHILADELPHIA, June 1, 2023 /PRNewswire/ -- Kang Haggerty LLC announced today that they obtained a $9 Million settlement in a non-intervened fentanyl false claims act qui tam case against private equity firm Belhealth Investment Partners, its principals, Harold Blue, Inder Tallur, and Dennis Drislane, and its pharmacy portfolio companies, Linden Care and Quick Care.
  • The parties have agreed to settle alleged violations of the False Claims Act (FCA) based on a complaint originally filed in 2016, asserting that the settling defendants violated the False Claims Act, §§ 3729-3722, and related laws, by conspiring to submit, submitting, and/or causing the submission of false claims for payment to the federal and state governments for prescriptions of Subsys, a potent, rapid-onset fentanyl sublingual spray.
  • The federal government and seven state governments intervened in this case (and four other FCA cases) in 2018 only as to the claims against Defendant Insys Therapeutics, Inc., the well-known defunct manufacturer of Subsys.
  • Approximately $1.7 billion (or 30%) of the amount recovered in 2021 was a result of qui tam filings.

The Inner Circle Acknowledges, Rany T. Abdallah, MD, Ph.D., MBA, as a Most Trusted Healthcare Professional for his contributions to the Medical Field

Retrieved on: 
Wednesday, May 3, 2023

WILMINGTON, Del., May 3, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Rany T. Abdallah, MD, Ph.D., MBA, is acknowledged as a Most Trusted Healthcare Professional for his contributions to the Medical Field.

Key Points: 
  • WILMINGTON, Del., May 3, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Rany T. Abdallah, MD, Ph.D., MBA, is acknowledged as a Most Trusted Healthcare Professional for his contributions to the Medical Field.
  • Dr. Abdallah began his educational journey at the Medical University of South Carolina where he earned a Medical Degree and Doctor of Philosophy degree (Ph.D.).
  • He then completed his residency in anesthesiology at Rush University in Chicago and his fellowship in pain medicine at the University of Pittsburgh, where he served as Chief Fellow.
  • As a pain management specialist, his focus is on pain medicine, evaluation, treatment, and prevention of pain.

Rany T. Abdallah, MD, Ph.D., is recognized by Continental Who's Who

Retrieved on: 
Wednesday, January 4, 2023

Dr. Abdallah earned his medical degree and Doctor of Philosophy degree (Ph.D.) at the Medical University of South Carolina.

Key Points: 
  • Dr. Abdallah earned his medical degree and Doctor of Philosophy degree (Ph.D.) at the Medical University of South Carolina.
  • Dr. Abdallah is the Owner/President of APICO Pain Management, serving patients in the Bear, Dover, and Millsboro areas.
  • A pain management specialist is a doctor who specializes in pain medicine, focusing on the evaluation, treatment, and prevention of pain.
  • In his free time, Dr. Abdallah likes to travel and is fluent in English, Arabic, French, and Spanish.

International Collaboration to Improve Cancer Care in Sub-Saharan Africa Focuses on Resources for Children's Cancers

Retrieved on: 
Thursday, December 15, 2022

DAR ES SALAAM, Tanzania and PLYMOUTH MEETING, Pa., Dec. 15, 2022 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers in the United States—is working on new NCCN Harmonized Guidelines™ for Sub-Saharan Africa, in collaboration with the African Cancer Coalition (ACC), the American Cancer Society (ACS), and the Clinton Health Access Initiative (CHAI). The organizations are part of Allied Against Cancer, a global multi-sector effort to improve resource-stratified access to life-saving cancer care in Sub-Saharan Africa. These harmonized guidelines build on the successful implementation of evidence-based, expert consensus context-appropriate recommendations for managing nearly all adult cancers across more than a dozen countries throughout the region. The groups recently reunited in Dar es Salaam, Tanzania to launch four additional NCCN Harmonized Guidelines™ specifically focused on best practices for treating children with cancer.

Key Points: 
  • The organizations are part of Allied Against Cancer, a global multi-sector effort to improve resource-stratified access to life-saving cancer care in Sub-Saharan Africa.
  • NCCN Harmonized Guidelines use color-coded recommendations for optimal cancer care in high-resource settings alongside pragmatic modifications for effective treatment options in low- and mid-resource settings.
  • The National Comprehensive Cancer Network ( NCCN ) is a not-for-profit alliance of leading cancer centers devoted to patient care, research, and education.
  • NCCN is dedicated to improving and facilitating quality, effective, equitable, and accessible cancer care so all patients can live better lives.

International Collaboration to Improve Cancer Care in Sub-Saharan Africa Focuses on Resources for Children's Cancers

Retrieved on: 
Thursday, December 15, 2022

DAR ES SALAAM, Tanzania and PLYMOUTH MEETING, Pa., Dec. 15, 2022 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers in the United States—is working on new NCCN Harmonized Guidelines™ for Sub-Saharan Africa, in collaboration with the African Cancer Coalition (ACC), the American Cancer Society (ACS), and the Clinton Health Access Initiative (CHAI). The organizations are part of Allied Against Cancer, a global multi-sector effort to improve resource-stratified access to life-saving cancer care in Sub-Saharan Africa. These harmonized guidelines build on the successful implementation of evidence-based, expert consensus context-appropriate recommendations for managing nearly all adult cancers across more than a dozen countries throughout the region. The groups recently reunited in Dar es Salaam, Tanzania to launch four additional NCCN Harmonized Guidelines™ specifically focused on best practices for treating children with cancer.

Key Points: 
  • The organizations are part of Allied Against Cancer, a global multi-sector effort to improve resource-stratified access to life-saving cancer care in Sub-Saharan Africa.
  • NCCN Harmonized Guidelines use color-coded recommendations for optimal cancer care in high-resource settings alongside pragmatic modifications for effective treatment options in low- and mid-resource settings.
  • The National Comprehensive Cancer Network ( NCCN ) is a not-for-profit alliance of leading cancer centers devoted to patient care, research, and education.
  • NCCN is dedicated to improving and facilitating quality, effective, equitable, and accessible cancer care so all patients can live better lives.

Goodness Growth Holdings Celebrates the Life and Legacy of Dr. Jay Westwater with Special Event

Retrieved on: 
Tuesday, December 6, 2022

MINNEAPOLIS, Minn., Dec. 6, 2022 /PRNewswire/ -- Goodness Growth Holdings, Inc. ("Goodness Growth" or the "Company") (CSE: GDNS; OTCQX: GDNSF), a physician-led, science-focused cannabis company and IP developer, today announced that it celebrated the life and legacy of Dr. Jay Westwater and the continued advancement of research into cannabis and cancer with a special event on Thursday, Dec. 1.

Key Points: 
  • At the Dec. 1 event, members of Dr. Westwater's family joined representatives from Goodness Growth and other community participants to celebrate his life and the impact he had on his patients and the greater Minneapolis community.
  • Representatives from the Minnesota Office of Medical Cannabis and Dr. Westwater's former coworkers from United Hospital in St. Paul also attended.
  • Goodness Growth also launched its new "Dr. Westwater" brand, a line of topical cannabis products named in honor of Dr. Westwater, at the event.
  • Goodness Growth Holdings, Inc., is a physician-led, science-focused holding company whose mission is to bring the power of plants to the world.

Grünenthal and Kyowa Kirin International Announce Joint Venture Collaboration for Established Medicines Portfolio

Retrieved on: 
Thursday, November 24, 2022

Kyowa Kirin Co., Ltd., (TSE:4151, President and CEO: Masashi Miyamoto, Kyowa Kirin), a Japan-based global specialty pharmaceutical company, and Grnenthal GmbH (CEO: Gabriel Baertschi), a global, science-based, privately-owned pharmaceutical company, are today announcing they have signed a Joint Venture Collaboration for Kyowa Kirin International's established medicines portfolio.

Key Points: 
  • Kyowa Kirin Co., Ltd., (TSE:4151, President and CEO: Masashi Miyamoto, Kyowa Kirin), a Japan-based global specialty pharmaceutical company, and Grnenthal GmbH (CEO: Gabriel Baertschi), a global, science-based, privately-owned pharmaceutical company, are today announcing they have signed a Joint Venture Collaboration for Kyowa Kirin International's established medicines portfolio.
  • The Joint Venture Collaboration is subject to obtaining customary approvals and clearances, including anti-trust and works councils as legally required.
  • Grnenthal will make an additional payment upon purchase of the remaining share and the intellectual property (IP) of the portfolio.
  • Kyowa Kirin International is a subsidiary of Kyowa Kirin Co., Ltd.
    Grnenthal is a global leader in pain management and related diseases.

Global Pain Management Drugs Market Demand and Pipeline Insights 2022 - ResearchAndMarkets.com

Retrieved on: 
Friday, October 21, 2022

The "Global Pain Management Drugs Market Demand and Pipeline Insights (2022 Edition) - Analysis By Drug Type, Route of Administration, End-Use, Availability, Sales Channel, By Region, By Country: Market Insights & Forecast with Impact of COVID-19 (2023-2028)" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Pain Management Drugs Market Demand and Pipeline Insights (2022 Edition) - Analysis By Drug Type, Route of Administration, End-Use, Availability, Sales Channel, By Region, By Country: Market Insights & Forecast with Impact of COVID-19 (2023-2028)" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • The global pain management drugs market is driven by an increasing number of Chronic Pain diseases and the prevalence of cancer pain worldwide.
  • This is likely to drive demand for many Pain Management drugs for advanced stages of cancer, chronic pain conditions and post-operative pain management drugs.
  • The report analyses the Pain Management Drugs Market by End use (Inflammation, Neuropathic Pain, Musculoskeletal Pain, Severe and Chronic Pain).

Global Cancer Pain Market Report 2022: Industry set to Grow by 5.71% Annually Through 2029 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 12, 2022

The "Cancer Pain Market Analysis by Disease Indication, by Drug Type, and by Region - Global Forecast to 2029" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cancer Pain Market Analysis by Disease Indication, by Drug Type, and by Region - Global Forecast to 2029" report has been added to ResearchAndMarkets.com's offering.
  • The cancer pain market size is estimated to be USD 6,599.12 million in 2021 and is expected to witness a CAGR of 5.71% during the forecast period 2022-2029.
  • This comprehensive research report focuses on the global and regional market size and forecasts of diverse segments including disease indication and drug type from 2021 to 2029.
  • Segmentation: Cancer Pain Market Report 2021-2029Disease Indication (Revenue, USD Million)